Patents by Inventor Peter C. Meltzer

Peter C. Meltzer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10399994
    Abstract: Disclosed herein are compounds, and pharmaceutical compositions that include such compounds, for preventing or treating hearing loss. The compounds and pharmaceutical compositions described herein prevent or treat hair cell death. In addition, the compounds and pharmaceutical compositions described herein protect against kidney damage in an individual receiving an aminoglycoside antibiotic. Methods of using the compounds, alone or in combination with other therapeutic agents, are also disclosed.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: September 3, 2019
    Assignees: University of Washington, Oricula Therapeutics LLC, Fred Hutchinson Cancer Research Center
    Inventors: Julian Simon, Graham Johnson, Edwin W. Rubel, David W. Raible, Mario D. Gonzalez, Peter C. Meltzer, Weishi Miao
  • Publication number: 20180022756
    Abstract: Disclosed herein are compounds, and pharmaceutical compositions that include such compounds, for preventing or treating hearing loss. The compounds and pharmaceutical compositions described herein prevent or treat hair cell death. In addition, the compounds and pharmaceutical compositions described herein protect against kidney damage in an individual receiving an aminoglycoside antibiotic. Methods of using the compounds, alone or in combination with other therapeutic agents, are also disclosed.
    Type: Application
    Filed: February 5, 2016
    Publication date: January 25, 2018
    Inventors: Julian Simon, Graham Johnson, Edwin W. Rubel, David W. Raible, Mario D. Gonzalez, Peter C. Meltzer, Weishi Miao
  • Patent number: 9493482
    Abstract: Disclosed herein are compounds, and pharmaceutical compositions that include such compounds, for preventing or treating hearing loss. The compounds and pharmaceutical compositions described herein prevent or treat hair cell death. In addition, the compounds and pharmaceutical compositions described herein protect against kidney damage in an individual receiving an aminoglycoside antibiotic. Methods of using the compounds, alone or in combination with other therapeutic agents, are also disclosed.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: November 15, 2016
    Assignees: University of Washington, Oricula Therapeutics LLC, Fred Hutchinson Cancer Research Center
    Inventors: Julian Simon, Graham Johnson, Edwin Rubel, David Raible, Mario D. Gonzalez, Peter C. Meltzer, Weishi Miao
  • Publication number: 20160229869
    Abstract: Disclosed herein are compounds, and pharmaceutical compositions that include such compounds, for preventing or treating hearing loss. The compounds and pharmaceutical compositions described herein prevent or treat hair cell death. In addition, the compounds and pharmaceutical compositions described herein protect against kidney damage in an individual receiving an aminoglycoside antibiotic. Methods of using the compounds, alone or in combination with other therapeutic agents, are also disclosed.
    Type: Application
    Filed: February 5, 2016
    Publication date: August 11, 2016
    Inventors: Julian SIMON, Graham JOHNSON, Edwin RUBEL, David RAIBLE, Mario D. GONZALEZ, Peter C. MELTZER, Weishi MIAO
  • Publication number: 20100143248
    Abstract: A method of diagnosing attention deficient-hyperactivity disorder (ADHD) in a human patient by assessing the level of dopamine transporter in at least one region of the patient's central nervous system, where an elevated level of dopamine transporter in the patient is indicative of ADHD. In embodiments of the invention, assessment of dopamine transporter levels includes assessing binding of a dopamine transporter ligand to the dopamine transporters using PET or SPECT.
    Type: Application
    Filed: June 23, 2009
    Publication date: June 10, 2010
    Applicants: President and Fellows of Harvard College, Organix, Inc., The General Hospital Corporation
    Inventors: Bertha K. Madras, Alan J. Fischman, Peter C. Meltzer
  • Publication number: 20090270626
    Abstract: The invention provides compounds and methods for preparing radiopharmaceutical compounds useful as therapeutic and diagnostic agents.
    Type: Application
    Filed: March 12, 2009
    Publication date: October 29, 2009
    Applicant: Organix, Inc.
    Inventor: Peter C. Meltzer
  • Publication number: 20090208415
    Abstract: The present invention provides novel tropane compounds and methods for their use.
    Type: Application
    Filed: December 11, 2008
    Publication date: August 20, 2009
    Applicants: President and Fellows of Harvard College, Organix, Inc.
    Inventors: Paul Blundell, Peter C. Meltzer, Bertha K. Madras
  • Patent number: 7553478
    Abstract: A method of diagnosing attention deficient-hyperactivity disorder (ADHD) in a human patient by assessing the level of dopamine transporter in at least one region of the patient's central nervous system, where an elevated level of dopamine transporter in the patient is indicative of ADHD. In embodiments of the invention, assessment of dopamine transporter levels includes assessing binding of a dopamine transporter ligand to the dopamine transporters using PET or SPECT.
    Type: Grant
    Filed: July 18, 2006
    Date of Patent: June 30, 2009
    Assignees: President and Fellows of Harvard College, Organix, Inc.
    Inventors: Bertha K. Madras, Alan J. Fischman, Peter C. Meltzer
  • Publication number: 20090048284
    Abstract: This invention to antagonists that inhibit transporters and receptors. The invention also relates to partial inhibitors of transporters and receptors that allow partial transport or partial binding of a compound to the transporter or receptor. The invention also relates to compounds that differentially prevent transport or binding through a transporter or to a receptor. The invention also relates to the use of these compounds for treating certain diseases and disorders.
    Type: Application
    Filed: October 21, 2008
    Publication date: February 19, 2009
    Inventors: Peter C. Meltzer, Bertha K. Madras, Paul Blundell, Shanghao Liu
  • Patent number: 7476740
    Abstract: The present invention provides novel tropane compounds and methods for their use.
    Type: Grant
    Filed: March 27, 2003
    Date of Patent: January 13, 2009
    Assignees: President and Fellows of Harvard College, Organix, Inc.
    Inventors: Paul Blundell, Peter C. Meltzer, Bertha K. Madras
  • Patent number: 7439264
    Abstract: This invention to antagonists that inhibit transporters and receptors. The invention also relates to partial inhibitors of transporters and receptors that allow partial transport or partial binding of a compound to the transporter or receptor. The invention also relates to compounds that differentially prevent transport or binding through a transporter or to a receptor. The invention also relates to the use of these compounds for treating certain diseases and disorders.
    Type: Grant
    Filed: February 10, 2003
    Date of Patent: October 21, 2008
    Assignees: President and Fellows of Harvard College, Organix, Inc.
    Inventors: Peter C. Meltzer, Bertha K. Madras, Paul Blundell, Shanghao Liu
  • Publication number: 20080234498
    Abstract: New compounds that bind to monoamine transporters are described. The compounds of the present invention can be racemic or pure R— or S-enantiomers. Certain preferred compounds of the present invention have a high selectively dopamine transporter versus the serotonin transporter. Preferred monoamine transporters for the practice of the present invention include the dopamine transporter, the serotonin transporter and the norepinephrine transporter.
    Type: Application
    Filed: October 8, 2004
    Publication date: September 25, 2008
    Applicants: PRESIDENT AND FELLOW OF HARVARD COLLEGE, ORGANIX, INC.
    Inventors: David Butler, Bertha K. Madras, Peter C. Meltzer
  • Patent number: 7199132
    Abstract: New tropane analogs that bind to monoamine transporters are described, particularly, 8-aza, 8carbo and 8-oxo tropanes having 6- or 7-hydroxyl or ketone substituents. The compounds of the present invention can be racemic, pure R-enantiomers, or pure S-enantiomers. Certain preferred compounds of the present invention have a high selectivity for the DAT versus the SERT. Also described are pharmaceutical therapeutic compositions comprising the compounds formulated in a pharmaceutically acceptable carrier and a method for inhibiting 5-hydroxy-tryptamine reuptake of a monoamine transporter by contacting the monoamine transporter with a 5-hydroxytryptamine reuptake inhibiting amount of a compound of the present invention. Preferred monoamine transporters for the practice of the present invention include the dopamine transporter, the serotonin transporter and the norepinephrine transporter.
    Type: Grant
    Filed: December 27, 2001
    Date of Patent: April 3, 2007
    Assignees: Organix, Inc., President and Fellows of Harvard College
    Inventors: Peter C. Meltzer, Bertha K. Madras, Paul Blundell
  • Patent number: 7105678
    Abstract: Radiopharmaceutical compounds are disclosed. A tropane compound is linked through the N atom at the 8-position to a chelating ligand capable of complexing technetium or rhenium to produce a neutral labeled complex that selectively binds to the dopamine transporter over the serotonin transporter with a ratio of 10 or more. These compounds can be prepared as separate diastereoisomers as well as a mixture of diastereoisomers. Also disclosed are radiopharmaceutical kits for preparing the labeled radiopharmaceutical compounds.
    Type: Grant
    Filed: October 11, 2001
    Date of Patent: September 12, 2006
    Assignees: Organix, Inc., President and Fellows of Harvard College, The General Hospital Corporation
    Inventors: Peter C. Meltzer, Paul Blundell, Bertha C. Madras
  • Patent number: 7081238
    Abstract: A method of diagnosing attention deficient-hyperactivity disorder (ADHD) in a human patient by assessing the level of dopamine transporter in at least one region of the patient's central nervous system, where an elevated level of dopamine transporter in the patient is indicative of ADHD. In embodiments of the invention, assessment of dopamine transporter levels includes assessing binding of a dopamine transporter ligand to the dopamine transporters using PET or SPECT.
    Type: Grant
    Filed: August 17, 2001
    Date of Patent: July 25, 2006
    Assignees: The President and Fellows of Harvard College, The General Hospital Corporation, Organix, Inc.
    Inventors: Bertha K. Madras, Alan J. Fischman, Peter C. Meltzer
  • Patent number: 7026516
    Abstract: Featured compounds have high monoamine transport affinity and are characterized by one of the following two general formulas set out above. The compounds bind selectively or non-selectively to monoamine transporters. The compounds are useful to treat various medical indications including attention deficit hyperactivity disorder (ADHD), Parkinson's disease, cocaine addiction, smoking cessation, weight reduction, obsessive-compulsive disorder, various forms of depression, traumatic brain injury, stroke, and narcolepsy.
    Type: Grant
    Filed: February 24, 2003
    Date of Patent: April 11, 2006
    Assignees: President and Fellows of Harvard College, Organix, Inc.
    Inventors: Peter C. Meltzer, Paul Blundell, Pinglang Wang, Bertha K. Madras
  • Publication number: 20040014992
    Abstract: Featured compounds have high monoamine transport affinity and are characterized by one of the following two general formulas set out above. The compounds bind selectively or non-selectively to monoamine transporters. The compounds are useful to treat various medical indications including attention deficit hyperactivity disorder (ADHD), Parkinson's disease, cocaine addiction, smoking cessation, weight reduction, obsessive-compulsive disorder, various forms of depression, traumatic brain injury, stroke, and narcolepsy.
    Type: Application
    Filed: February 24, 2003
    Publication date: January 22, 2004
    Inventors: Peter C. Meltzer, Paul Blundell, Pinglang Wang, Bertha K. Madras
  • Patent number: 6677338
    Abstract: The present invention relates to the therapeutic use of non-amine tropane analogues that bind to the SERT to treat neuropsychiatric disorders.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: January 13, 2004
    Assignees: President and Fellows of Harvard College, Organix, Inc.
    Inventors: Bertha K. Madras, Peter C. Meltzer
  • Patent number: 6670375
    Abstract: New tropane analogs that bind to monoamine transporters are described, particularly, 8-aza, 8carbo and 8-oxo tropanes having 6- or 7-substituents. The compounds of the present invention can be racemic, pure R-enantiomers, or pure S-enantiomers. Certain preferred compounds of the present invention have a high selectivity for the DAT versus the SERT. Also described are pharmaceutical therapeutic compositions comprising the compounds formulated in a pharmaceutically acceptable carrier and a method for inhibiting 5-hydroxy-tryptamine reuptake of a monoamine transporter by contacting the monoamine transporter with a 5-hydroxytryptamine reuptake inhibiting amount of a compound of the present invention. Preferred monoamine transporters for the practice of the present invention include the dopamine transporter, the serotonin transporter and the norepinephrine transporter.
    Type: Grant
    Filed: June 6, 2001
    Date of Patent: December 30, 2003
    Assignees: Organix, Inc., President and Fellows of Harvard College
    Inventors: Peter C. Meltzer, Bertha K. Madras, Paul Blundell, Zhengming Chen
  • Publication number: 20030232819
    Abstract: The present invention provides novel tropane compounds and methods for their use.
    Type: Application
    Filed: March 27, 2003
    Publication date: December 18, 2003
    Inventors: Paul Blundell, Peter C. Meltzer, Bertha K. Madras